The companies have signed a non-exclusive license deal, which follows a joint feasibility study. Under the study, Vectron’s genetic elements were tested for high-yield, soluble production of a
The European Commission (EC) has granted marketing authorization for Strensiq, which treats the bone manifestation of pediatric-onset hypophosphatasia (HPP). Alexion said HPP is a genetic and progressive metabolic
SGX942 is a first-in-class innate defense regulator (IDR) and is being evaluated as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck
The clinical trial, dubbed EVEREST, will evaluate the antiviral activity, safety and pharmacokinetics of a combination regimen of Danoprevir (ASC08), a direct-acting antiviral agent and NS3/4A inhibitor, and
The twice-a-day product can be used in adult males for conditions related with a deficiency or absence of endogenous testosterone (hypogonadism). The company’s oral androgen replacement (SOAR) pivotal
Under the terms of the agreement, Bristol-Myers will pay $150m in cash up front for the right to buy Promedior. Bristol-Myers can exercise its right after Promedior completes
The company will complete screening at participating sites in the next two weeks. Enrollment is anticipated to be completed by the end of the third quarter. Twirla is
Bacterial vaginosis (BV) is the most common vaginal infection in women of childbearing age which is caused due to an imbalance of naturally occurring vaginal bacterial flora. Laccure
Perrigo’s expansive distribution and customer network in the US will be used to boost ScarAway’s growth. ScarAway is expected to have net sales of around $10m in full,
The deal is part of the Belgian firm’s intention to expand the global footprint of C-Cure to treat ischemic heart failure. As part of the deal, Celyad will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.